Nutranomics Inc (OTCMKTS:NNRX) Stock Sees Selling Pressure At Higher Level

August 6, 2021

There were many stocks which did not have a particularly great time in the markets yesterday and one of those was the Nutranomics Inc (OTCMKTS:NNRX) stock. The stock suffered from a selloff yesterday and slumped by as much as 11% despite the emergence of fairly positive news about the company. Yesterday it emerged that the company had managed to get Pink Current status from the OTC Markets and it goes…

Read More >>

Ascent Solar Technologies Inc. (OTCMKTS:ASTI) Stock Extends Rally: Soars 30% in a Week

August 6, 2021

Ascent Solar Technologies Inc. (OTCMKTS:ASTI) jumped 10% and 28% in a week. The company announced the signing is a funding agreement with the investment holding unit of the German majority shareholders of the company, BD 1 Investment Holding LLC. Ascent Solar entered a securities purchase agreement with BD 1 on August 2, 2021, to sell 66.67 million shares of its common stock at the current market price of $0.015 per…

Read More >>

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Attempts To Bounce Back: A Value Buy?

August 6, 2021

Tonix Pharmaceuticals (NASDAQ:TNXP) stock is having a rough week after releasing a disappointing preliminary analysis from a late-stage clinical study that seems set to fail. The stock has since plunged below $1.Considering that Tonix’s other late-stage studies focus on difficult to treat conditions such as Alzheimer’s disease and PTSD, its outlook looks frail. However, bold investors may see the stumble as a chance to buy in, and they could be…

Read More >>

Will Jushi Holdings, Inc. (OTCMKTS:JUSHF) Stock Accelerate In 2021?

August 5, 2021

Jushi Holdings, Inc. (OTCMKTS:JUSHF) a company engaged in the ownership and operation of cannabis and hemp licenses in the United States is on an expansion spree with the opening of several new stores. These new openings would certainly generate handsome revenue for the company but that too doesnot guarantee for stock to soar high as the company is recently running out of the management’s hands. In the wake of the…

Read More >>

Is Cybin Inc (OTCMKTS:CLXPF) Stock a Good Buy After The Recent Rally?

August 5, 2021

Biotechnological company focusing on psychedelic therapeutics, Cybin Inc (OTCMKTS:CLXPF) on August 3, 2021, announced receiving conditional listing approval from the NYSE American stock exchange. CEO Doug Drysdale said that conditional approval is a vital milestone in the company’s journey. Drysdale said he expects expanded access for investors result in fueling the mission of developing revolutionary psychedelic therapeutics for patients having mental health conditions. However, the listing is subjected to approval…

Read More >>

SFLMaven Corp (OTCMKTS:SFLM) Stock Gains Momentum After The News

August 5, 2021

SFLMaven Corp (OTCMKTS:SFLM) jumped 17% after announcing the filing of its unaudited financial performance data for the period ended June 30, 2021, featuring a robust business activity expansion and solid bottom and top-line improvements. Total sales were up 14% YoY for the six months ended June 30, 2021, at $4.8 million. In addition, the company reported accelerated sales growth, with June sales jumping 125% YoY and gross profit was $688,423…

Read More >>

Alterity Therapeutics (ATHE) Stock Off Session High: Gets New Patent

August 4, 2021

A biotechnology company developing disease-modifying treatments for neurodegenerative conditions, Alterity Therapeutics (NASDAQ:ATHE) on August 4, 2021 announced the United States Patent and Trademark Office issuing Notice of Allowance for Alterity’s patent application No. 17/239,375. This would secure exclusivity for a fresh group of iron chaperones made for redistributing the excess iron in many neurodegenerative diseases, including Parkinson’s and Alzheimer’s. The patent, which is titled “Compounds for and Methods of Treating…

Read More >>

Moderna Inc (NASDAQ:MRNA) Stock Soars Above $400: All Eyes on Earnings Tomorrow

August 4, 2021

Moderna Inc (NASDAQ:MRNA) will report second quarter earnings tomorrow before the open. There is a conference call scheduled for 8:00 ET. Q2 Capital IQ consensus calls for EPS of $5.86 vs. ($0.31) last year on revenue of $4.233 billion versus $66.3 million last year. The company typically does not provide EPS or revenue guidance. The first area of interest will be the company’s COVID-19 vaccine. The company recently Increased 2021…

Read More >>

Aldeyra Therapeutics (NASDAQ:ALDX) Stock Moves Up After The Positive News

August 4, 2021

Aldeyra Therapeutics (NASDAQ:ALDX) announces that the U.S. FDA has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP), a group of rare genetic eye diseases. Shares up more than 6% premarket. There are no approved drug treatments for patients with RP, which is a disease affects an estimated 82,000-110,000 individuals in the United States. The FDA’s orphan drug designation program is designed…

Read More >>